Shares of Theratechnologies Inc. (NASDAQ:THTX) have been given an average broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Brokers have set a 1-year consensus target price of $6.94 for the company and are forecasting that the company will post ($0.03) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Theratechnologies an industry rank of 58 out of 255 based on the ratings given to its competitors.
A number of analysts have weighed in on THTX shares. Canaccord Genuity initiated coverage on Theratechnologies in a report on Monday, December 2nd. They set a “buy” rating for the company. ValuEngine raised Theratechnologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd.
Theratechnologies (NASDAQ:THTX) last released its earnings results on Tuesday, October 8th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $16.11 million during the quarter. Theratechnologies had a negative net margin of 11.57% and a negative return on equity of 14.72%. As a group, analysts forecast that Theratechnologies will post -0.05 EPS for the current year.
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.